Rebecca S. Hock, PhD

Clinical Trials Network and Institute, Department of Psychiatry, Massachusetts General Hospital; and Department of Psychiatry, Harvard Medical School, Boston, Massachusetts; Equal contribution.; Corresponding author: Rebecca S. Hock, PhD, 1 Bowdoin Sq, 9th Floor, Boston, MA 02114 ([email protected]).

JCP
Rapidity of Improvement With Intranasal Esketamine for MDD
Meta-Analysis

December 12, 2022

This meta-analysis found that augmenting antidepressants with intranasal esketamine vs placebo was more effective in reducing depression severity at 24 hours and study endpoint.
Rebecca S. Hock, Anna Feeney, Nadia Iovieno, et al
JCP
Meta-Analysis

June 15, 2021

Prior meta-analyses have found vortioxetine to be efficacious for depression. Building on those findings, the present meta-analysis examined the effect that placebo response has on drug-placebo effect size in...
Nadia Iovieno, George I. Papakostas, Anna Feeney, et al
JCP
Meta-Analysis

May 26, 2020

The FDA has now approved intranasal esketamine as augmention in treatment-resistant depression, and recent studies of its efficacy have been encouraging. This meta-analysis synthesizes the evidence to provide an...
George I. Papakostas, Naji C. Salloum, Rebecca S. Hock, et al
JCP
Original Research

August 5, 2014

Yoichiro Takayanagi, Adam P. Spira, O. Joseph Bienvenu, et al

Celebrating
85 Years

Read the Journal of Clinical Psychiatry

Subscribe to read
more articles

Subscribe